Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT-1X in advanced prostate cancer

Citation
Sh. Garrett et al., Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT-1X in advanced prostate cancer, PROSTATE, 43(2), 2000, pp. 125-135
Citations number
19
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
PROSTATE
ISSN journal
02704137 → ACNP
Volume
43
Issue
2
Year of publication
2000
Pages
125 - 135
Database
ISI
SICI code
0270-4137(20000501)43:2<125:MI1A2G>2.0.ZU;2-2
Abstract
BACKGROUND. Studies have shown an association of metallothionein (MT) overe xpression with tumor type and grade. However, a family of genes underlies t he expression of these proteins. The goals of this study were to define the expression of MT genes and protein in normal human prostate and to provide evidence that the expression of the MT isoforms is altered in prostate can cer. METHODS, Immunohistochemistry was used to localize MT protein, reverse traf iscription-polymerase chain reaction (RT-PCR) to determine the MT isoform-s pecific mRNAs, and immunoblot analysis to determine MT protein levels. RESULTS. The localization of MT in the prostate was further defined using t he E9 antibody. Using normal prostate tissue dissected from glands removed for prostate cancer, it was demonstrated that MT protein expression in the normal prostate is supported by mRNA from the MT-1A, MT-1E, MT-1X, and MT-2 A genes. No expression of the MT-1X gene was demonstrated in cases of advan ced prostate cancer. The expression of MT-1 and MT-2 isoform-specific mRNA varied among three commonly utilized prostate cancer cell lines. CONCLUSIONS. MT protein in the normal human prostate is supported by transc ription of mRNA from the MT-1A, MT-1E, MT-1X, and MT-2A genes. Expression o f MT-1X mRNA is downregulated in advanced prostate cancer. Variable express ion of MT mRNA in prostate cell lines provides evidence that MT gene expres sion may be altered among individual prostate cancers. (C) 2000 Wiley-Liss, Inc.